Quarterly report pursuant to Section 13 or 15(d)

Licensed Technology (Details Narrative)

v3.20.1
Licensed Technology (Details Narrative) - USD ($)
3 Months Ended
Apr. 17, 2020
Apr. 01, 2020
Nov. 04, 2018
May 15, 2015
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Nov. 04, 2019
Due to licensor current         $ 28,000,000   $ 27,400,000  
Interest payable               $ 1,000,000
Non-cash licensed technology impairment charge         32,916,000    
Amortization of intangible assets         $ 1,294,000 $ 1,345,000    
Abeona Therapeutics Llc [Member]                
Finite-lived intangible asset, useful life       20 years        
Subsequent Event [Member]                
Guaranteed and payable   $ 20,000,000            
Maturity date   Nov. 04, 2020            
Royalties payments   $ 8,000,000            
License to be paid $ 8,000,000              
License termination date May 02, 2020              
Termination penalties $ 28,000,000              
Original License Agreements [Member]                
License to be paid               10,000,000
Amended Agreements [Member]                
License to be paid               3,000,000
Amended Agreements [Member] | April 1, 2020 [Member]                
License to be paid               $ 8,000,000
REGENXBIO [Member] | Licensing Agreements [Member]                
Royalty fees     $ 180,000,000          
Guaranteed upfront payment     20,000,000          
Payment on Execution of Contracts     10,000,000          
Due to licensor current     10,000,000          
Annual fees     100,000,000          
Guaranteed and payable     $ 20,000,000          
Maturity date     Nov. 04, 2020          
Royalties payments     $ 60,000,000          
Finite-lived intangible asset, useful life     8 years